Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Botanix Pharmaceuticals Limited ( (AU:BOT) ) just unveiled an announcement.
Botanix Pharmaceuticals Limited has announced the cessation of several securities due to the lapse of conditional rights, as the conditions for these securities have not been met or have become incapable of being satisfied. This announcement may impact the company’s financial structuring and could influence investor perceptions, potentially affecting its market positioning.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
More about Botanix Pharmaceuticals Limited
Botanix Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development and commercialization of dermatology and antimicrobial products. The company is known for its innovative approach to addressing unmet needs in skin health and infection management.
Average Trading Volume: 8,929,196
Technical Sentiment Signal: Sell
Current Market Cap: A$315.3M
For detailed information about BOT stock, go to TipRanks’ Stock Analysis page.